Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says

By Adam Whittaker

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer.

The Swiss pharmaceutical company said Tuesday that late-stage trials showed the combination led to a 46% reduction in the risk of the disease progressing or death, and 27% reduction in the risk of death.

The combination can be used a as a first-line maintenance treatment for people with the cancer following induction therapy with carboplatin, etoposide and Tecentriq, it said.

The safety profile of the combination was consistent with the known safety profiles of Tecentriq and lurbinectedin, Roche said.

Write to Adam Whittaker at [e-mail]

(END) Dow Jones Newswires

06-03-25 0148ET